Literature DB >> 31646453

Propensity-Matched Analysis Comparing Survival After Sublobar Resection and Lobectomy for cT1N0 Lung Adenocarcinoma.

Xu-Heng Chiang1, Hsao-Hsun Hsu1, Min-Shu Hsieh2, Chia-Hong Chang3, Tung-Ming Tsai1, Hsien-Chi Liao1, Kuan-Chuan Tsou4, Mong-Wei Lin5, Jin-Shing Chen1.   

Abstract

BACKGROUND: The optimal surgical method for cT1N0 lung adenocarcinoma remains controversial.
OBJECTIVE: The aim of this study was to evaluate the differences in clinical outcomes of sublobar resection and lobectomy for cT1N0 lung adenocarcinoma patients.
METHODS: We included 1035 consecutive patients with cT1N0 lung adenocarcinoma who underwent surgery at our institute from January 2011 to December 2016. The surgical approach, either sublobar resection or lobectomy, was determined at the discretion of each surgeon. A propensity-matched analysis incorporating total tumor diameter, solid component diameter, consolidation-to-tumor (C/T) ratio, and performance status was used to compare the clinical outcomes of the sublobar resection and lobectomy groups.
RESULTS: Sublobar resection and lobectomy were performed for 604 (58.4%; wedge resection/segmentectomy: 470/134) and 431 (41.6%) patients, respectively. Patients in the sublobar resection group had smaller total tumor diameters, smaller solid component diameters, lower C/T ratios, and better performance status. More lymph nodes were dissected in the lobectomy group. Patients in the sublobar resection group had better perioperative outcomes. A multivariable analysis revealed that the solid component diameter and serum carcinoembryonic antigen level are independent risk factors for tumor recurrence. After propensity matching, 284 paired patients in each group were included. No differences in overall survival (OS; p = 0.424) or disease-free survival (DFS; p = 0.296) were noted between the two matched groups.
CONCLUSIONS: Sublobar resection is not inferior to lobectomy regarding both DFS and OS for cT1N0 lung adenocarcinoma patients. Sublobar resection may be a feasible surgical method for cT1N0 lung adenocarcinoma.

Entities:  

Year:  2019        PMID: 31646453     DOI: 10.1245/s10434-019-07974-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Development and validation of a deep learning signature for predicting lymph node metastasis in lung adenocarcinoma: comparison with radiomics signature and clinical-semantic model.

Authors:  Xiaoling Ma; Liming Xia; Jun Chen; Weijia Wan; Wen Zhou
Journal:  Eur Radiol       Date:  2022-09-28       Impact factor: 7.034

2.  Surgical Options for Resectable Lung Adenosquamous Carcinoma: A Propensity Score-Matched Analysis.

Authors:  Shuncang Zhu; Tao Ge; Yicheng Xiong; Jing Zhang; Di Zhu; Liangdong Sun; Nan Song; Peng Zhang
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

3.  Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?

Authors:  Boyu Lin; Rui Wang; Liang Chen; Zhitao Gu; Chunyu Ji; Wentao Fang
Journal:  Transl Lung Cancer Res       Date:  2021-06

4.  Thoracoscopic Lobectomy Versus Sublobar Resection for pStage I Geriatric Non-Small Cell Lung Cancer.

Authors:  Young-Jen Lin; Xu-Heng Chiang; Tzu-Pin Lu; Min-Shu Hsieh; Mong-Wei Lin; Hsao-Hsun Hsu; Jin-Shing Chen
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

5.  Factors Associated with Nodal Upstaging in Clinical T1a-bN0M0 Non-Small Cell Lung Cancers.

Authors:  Tung-Ming Tsai; Chao-Yu Liu; Mong-Wei Lin; Hsao-Hsun Hsu; Jin-Shing Chen
Journal:  Cancers (Basel)       Date:  2022-03-01       Impact factor: 6.639

6.  Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early-stage large-cell neuroendocrine carcinoma.

Authors:  Claudio Andreetti; Mohsen Ibrahim; Antonio Gagliardi; Camilla Poggi; Giulio Maurizi; Domenico Armillotta; Valentina Peritone; Leonardo Teodonio; Erino Angelo Rendina; Federico Venuta; Marco Anile; Giovanni Natale; Mario Santini; Alfonso Fiorelli
Journal:  Thorac Cancer       Date:  2022-02-16       Impact factor: 3.500

7.  Automated 3D Segmentation of the Aorta and Pulmonary Artery on Non-Contrast-Enhanced Chest Computed Tomography Images in Lung Cancer Patients.

Authors:  Hao-Jen Wang; Li-Wei Chen; Hsin-Ying Lee; Yu-Jung Chung; Yan-Ting Lin; Yi-Chieh Lee; Yi-Chang Chen; Chung-Ming Chen; Mong-Wei Lin
Journal:  Diagnostics (Basel)       Date:  2022-04-12

Review 8.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors.

Authors:  Brett C Bade; Justin D Blasberg; Vincent J Mase; Ulas Kumbasar; Andrew X Li; Henry S Park; Roy H Decker; David C Madoff; Whitney S Brandt; Gavitt A Woodard; Frank C Detterbeck
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

9.  Prognostic impact of lymphadenectomy on outcomes of sublobar resection for non-small cell lung cancer ≤1 or >1 to 2 cm.

Authors:  Enkuo Zheng; Minglei Yang; Rui Li; Junjun Ni; Xiang Xu; Guofang Zhao
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

10.  Combination of electromagnetic navigation bronchoscopy-guided microwave ablation and thoracoscopic resection: An alternative for treatment of multiple pulmonary nodules.

Authors:  Ning Jiang; Liming Zhang; Yingtao Hao; Xiaolin Wu; Yunpeng Zhao; Bo Cong; Chuanliang Peng
Journal:  Thorac Cancer       Date:  2020-04-14       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.